Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Rationale: The ability to treat invalidating neurological diseases is impeded by the presence of the blood-brain barrier (BBB), which inhibits the transport of most blood-borne substances into the brain parenchyma.Targeting the transferrin receptor (TfR) on the surface of brain capillaries has been a popular strategy to give a preferential accumulation of drugs or nanomedicines, but several aspects of this targeting strategy remain elusive.Here we report that TfR-targeted gold nanoparticles (AuNPs) can accumulate in brain capillaries and further transport across the BBB to enter the brain parenchyma.Methods: We characterized our targeting strategy both in vitro using primary models of the BBB and in vivo using quantitative measurements of gold accumulation by inductively-coupled plasma-mass spectrometry together with morphological assessments using light microscopy after silver enhancement and transmission electron microscopy with energy-dispersive X-ray spectroscopy.Results: We find that the uptake capacity is significantly modulated by the affinity and valency of the AuNP-conjugated antibodies.Specifically, antibodies with high and low affinities mediate a low and intermediate uptake of AuNPs into the brain, respectively, whereas a monovalent (bi-specific) antibody improves the uptake capacity remarkably.Conclusion: Our findings indicate that monovalent ligands may be beneficial for obtaining transcytosis of TfR-targeted nanomedicines across the BBB, which is relevant for future design of nanomedicines for brain drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“The low accumulation of drugs in the brain is due to the presence of the blood-brain barrier (BBB), which restricts passage of most compounds into the brain [3].”
BackgroundSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Nance, E. A., Woodworth, G. F., Sailor, K. A., Shih, T.-Y., Xu, Q., Swaminathan, G., Xiang, D., Eberhart, C., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003594 · Cited by 649 · cited 1×
“Some suggest the width of the brain extracellular space to be maximum 64 nm [63], whereas others claim that nanoparticles of 100 nm can move in this compartment [64, 65].”
BackgroundThorne, R. G., & Nicholson, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509425103 · Cited by 641
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Pizzo, M. E., Wolak, D. J., Kumar, N. N., Brunette, E., Brunnquell, C. L., Hannocks, M., Abbott, N. J., Meyerand, M. E., Sorokin, L., Stanimirovic, D. B., et al. (2018) · The Journal of Physiology · doi:10.1113/jp275105 · Cited by 272 · cited 1×
“Whether nanoparticles and other large molecules are mobile in the brain extracellular space after transcytosis from the systemic circulation is still a matter of dispute, and their diffusion properties remain poorly understood [62].”
Background6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218 · cited 1×
“Whether active targeting is required in the case of manifest neurological disease with possible loss of BBB integrity is widely discussed [35-38].”
Background
Cited by
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
Zhang, W., Mehta, A., Tong, Z., Esser, L., & Voelcker, N. H. (2021) · Advanced Science · doi:10.1002/advs.202003937 · Cited by 430
Drug delivery to the central nervous system
Nance, E., Pun, S. H., Saigal, R., & Sellers, D. L. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00394-w · Cited by 414
Advances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 395
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Self-citationDevelopment of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Kucharz, K., Kristensen, K., Johnsen, K. B., Lund, M. A., Lønstrup, M., Moos, T., Andresen, T. L., & Lauritzen, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-24323-1 · Cited by 123
Self-citationKang, S., Duan, W., Zhang, S., Chen, D., Feng, J., & Qi, N. (2020) · Theranostics · doi:10.7150/thno.41322 · Cited by 91
Nájera-Maldonado, L., Parra-González, M., Peralta-Cuevas, E., Gutierrez-Onofre, A. J., Garcia-Atutxa, I., & Villanueva-Flores, F. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091169 · Cited by 40
“LDL receptor-targeted PLGA NPs achieved a ~4% ID/g brain concentration compared to a ~1% ID/g concentration for untargeted NPs [24,85].”
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Johnsen, K. B., Bak, M., Kempen, P. J., Melander, F., Burkhart, A., Thomsen, M. S., Nielsen, M. S., Moos, T., & Andresen, T. L.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 12
- Pages
- 3416-3436
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2807149247
- Cited by
- 156
- References
- 13
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.